ASRT | tickerfilter.com

Fundamental analysis

50%

Profitability 40%

Dept financing 38%

Liquidity 69%

Performance 58%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.42%

1 Month

-2.50%

3 Months

1,401.99%

6 Months

1,356.08%

1 Year

1,398.91%

2 Year

1,185.51%

Key data

Stock price

$11.72

P/E Ratio

0.00

DAY RANGE

$11.50 - $11.85

EPS

-$0.16

52 WEEK RANGE

$0.51 - $12.95

52 WEEK CHANGE

$1,437.86

MARKET CAP

84.768 M

YIELD

N/A

SHARES OUTSTANDING

96.252 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-05-2025

BETA

1.08

PUBLIC FLOAT

AVERAGE 10 VOLUME

$34,317

AVERAGE 30 VOLUME

$38,403

Company detail

CEO: Daniel A. Peisert
Region: US
Website: assertiotx.com
Employees: 20
IPO year: 2020

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Assertio Holdings, Inc. provides medicines in neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the. treatment of migraine, nausea, photophobia, and phonophobia.

ASRT - Assertio Holdings, Inc.